Company: PRTA
Filing Date: 2025-03-28
Form Type: DEF 14A
Source: 0001559053-25-000017
Chunk: 33

Company: PROTHENA CORP PUBLIC LTD CO
Filing Date: 2025-03-28
Form: DEF 14A
Chunk 33
---
 such vesting date), and have a ten-year term. In the case of Mr. Welch, the amount reported represents the following: (a) the grant date fair value of options granted on February 21, 2024, to acquire 132,000 shares, which options have an exercise price of $27.05 per share (the fair market value per share on the date of grant), vest in equal annual installments over five years following the grant date (subject to continuous service as a director until each such vesting date), and have a ten-year term; and (b) the grant date fair value of options granted on May 15, 2024, to acquire 15,000 shares, which options have an exercise price of $22.39 per share (the fair market value per share on the date of grant), vest on the earlier of the first anniversary of the grant date or the day of the next annual general meeting of shareholders (subject to continuous service as a director until such vesting date), and have a ten-year term.

(3) Consists of consulting fees paid pursuant to a consulting arrangement with the Company’s wholly-owned subsidiary, Prothena Biosciences Inc, under which Dr. Selkoe provides consulting services in connection with matters related to the Company’s partnered collaboration programs.

(4) Dr. Härfstrand’s term expired on May 14, 2024, and his cash compensation was pro-rated for his service as a director in fiscal year 2024.

(5) Mr. Nodelman has declined to receive any cash or equity compensation for his service as a director.

(6) Mr. Welch was appointed to the Board on February 21, 2024, and his cash compensation was pro-rated for his service as a director in fiscal year 2024.

| 2025 PROXY STATEMENT |     | 19 |

TABLE OF CONTENTS

| DIRECTOR COMPENSATION - FISCAL YEAR 2024 |

As of the end of our fiscal year 2024, the total number of shares subject to outstanding option awards held by each non-employee director serving during fiscal year 2024 were as set forth in the following table. No other equity awards were held by our non-employee directors as of the end of our fiscal year 2024.

| Name                    |     | Outstanding   
 Option Awards 
 (Shares)      |         |
| Paula K. Cobb           |     |               | 112,500 |
| Richard T